Contribute Try STAT+ Today

Tempus, the medical technology company founded and run by the billionaire behind the digital coupon site Groupon, announced this morning that it is launching a new service that will use artificial intelligence to get more patients into clinical trials for cancer.

Eric Lefkofsky, the founder and chief executive of Tempus, started the company after being shocked at the disorganization of the medical system when his wife developed breast cancer. (He’s said she’s doing well.) His past success and the scale of his vision — combining genomics, AI, and collaboration with top cancer centers — has allowed him to raise a startling amount of money. Last week, Tempus raised $200 million from investors including Baillie Gifford, Franklin Templeton Investments, and New Enterprise Associates, bringing the total amount the company has raised to $520 million and valuing Tempus at $3.1 billion.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED

What is it?

STAT+ is STAT's premium subscription service for in-depth biotech, pharma, policy, and life science coverage and analysis. Our award-winning team covers news on Wall Street, policy developments in Washington, early science breakthroughs and clinical trial results, and health care disruption in Silicon Valley and beyond.

What's included?

  • Daily reporting and analysis
  • The most comprehensive industry coverage from a powerhouse team of reporters
  • Subscriber-only newsletters
  • Daily newsletters to brief you on the most important industry news of the day
  • STAT+ Conversations
  • Weekly opportunities to engage with our reporters and leading industry experts in live video conversations
  • Exclusive industry events
  • Premium access to subscriber-only networking events around the country
  • The best reporters in the industry
  • The most trusted and well-connected newsroom in the health care industry
  • And much more
  • Exclusive interviews with industry leaders, profiles, and premium tools, like our CRISPR Trackr.